Hannah Harris Green

Brazilian HIV advocates say the country’s constitutionally guaranteed healthcare system and publicly funded Unified Health System have shielded its HIV prevention and treatment programs from foreign-aid cuts, helping it eliminate mother-to-child HIV transmission in 2025. Gestos representative Juliana Cesar says restrictive donor conditions around sexual and reproductive health and LGBTQ+ communities made reductions in aid foreseeable. Advocates argue that domestic financing, local production of medicines and mechanisms such as health-focused transaction taxes could give countries greater autonomy. They also say aid currently used for narcotics policing could instead support syringes and other prevention measures, while warning that reliance on unpaid frontline labor is not sustainable. Brazil still faces limits on access to newer treatments and possible research impacts from NIH cuts.

Lenacapavir, a twice-yearly injectable form of HIV pre-exposure prophylaxis, could substantially reduce new infections among people who face barriers to daily or frequent healthcare access. WHO- and UN-backed modeling estimates that broad availability could prevent 41% of new infections in South Africa, Zimbabwe and western Kenya. Experts warn, however, that the Trump administration's dissolution of USAID—previously responsible for 73% of donor-funded global HIV-prevention resources—has coincided with steep declines in prevention investment, service closures and the loss of peer outreach workers. Advocates also criticize pharmaceutical access agreements that exclude several Latin American countries, arguing that current funding and pricing barriers could prevent the most vulnerable populations from benefiting from promising prevention advances.

Recent recalls of multiple infant formula brands amid bacterial contamination concerns have drawn attention to significant staff losses and reduced inspection capacity at the FDA following Trump-era cuts. Experts warn that limited oversight, especially for ingredient suppliers and foreign manufacturers, has hampered coordinated safety efforts, leaving states to fill regulatory gaps. Ongoing investigations link outbreaks to shared milk powder suppliers, while companies implement new safety measures. Broader systemic risks, including weakened multi-agency food safety structures and climate change, compound vulnerabilities in the U.S. formula supply chain.

A review at San Francisco General Hospital identified several non‑opioid medications with potential to relieve common emergency‑department pain, including acetaminophen, ibuprofen, ketamine, SNRIs, antipsychotics and gabapentin. Researchers Akash Shanmugam and Kathy LeSaint emphasized that opioids remain useful but alternatives can offer safer options, with effectiveness varying by pain type and patient genetics. Psychotropic medications may aid pain relief by regulating neurotransmitters involved in both mood and pain perception. Clinicians are encouraged to tailor treatment based on patient history and ensure patients understand that psychiatric medications for pain do not imply symptoms are psychological.

A review study in JAMA Network Open finds that diagnostic interviews used to assess mental and substance use disorders vary widely in reliability, with substance use disorders showing the highest consistency. Lead author Laura Duncan argues that diagnostic interviews are treated as a gold standard despite limited evidence of strong validity. Columbia University professor Michael First criticizes gaps in the study, including lack of detail on specific diagnostic instruments and the grouping of structured and semi-structured interviews. The findings highlight insufficient data on interview formats and a broader need for more rigorous psychiatric diagnostic tools, with experts noting that structured interviews have limitations and that future approaches may rely on symptom continua rather than strict diagnostic categories.

Research highlighted by the American Journal of Public Health shows major tobacco companies applied cigarette marketing and product design strategies to ultra-processed foods, including optimizing formulations to encourage repeat consumption and creating child-targeted products like Lunchables. Experts cited growing evidence linking high UPF consumption to increased health risks such as dementia, cardiovascular disease and certain cancers. Scholars described how companies including Philip Morris adapted tactics like “light” product lines to retain customers, while also acquiring smaller food businesses to expand influence. Public health experts criticized current U.S. policy decisions under the Trump administration for exacerbating industry advantages and failing to support healthier food access, particularly through subsidies and the Supplemental Nutrition Assistance Program.

A study published in Nature Human Behaviour finds that growing Republican mistrust in the healthcare system is widening health disparities with Democrats, driven by declining trust in doctors, reduced use of medical care and resistance to vaccines. Researchers attribute the trend partly to longstanding education-based political polarization and partly to intensified anti‑authority attitudes during and after the Covid‑19 pandemic. Experts warn that vaccine hesitancy has expanded to include long‑established immunizations and is now embedded in policies across several Republican-led states. The shift is contributing to higher rates of hypertension, cardiovascular disease and long Covid among conservatives, and researchers call for more consistent tracking of political factors in major health surveys.

Mordecai Kurz argues that concentrated technological power in the US has produced extreme monopoly conditions that undermine democracy, linking today’s tech oligarchs to earlier industrial magnates. He attributes political polarization and the rise of Maga to economic disenfranchisement fueled by deregulation and weakened antitrust enforcement. Kurz warns that tech giants’ economic dominance, lobbying strength and influence over social media accelerate democratic erosion, and predicts AI will intensify job displacement across professions. Despite anticipating potential crises ahead, he expects a new reform cycle driven by public dissatisfaction, calling for taxation of monopoly wealth, government‑supported worker retraining and regulations ensuring AI augments rather than replaces labor.

A clinical trial published in Jama Network Open found that a single dose of psilocybin, paired with therapy, increased abstinence from cocaine compared with a diphenhydramine placebo. Researchers highlight the urgency of treatments for stimulant addiction and suggest that psilocybin’s ability to enhance neuroplasticity may support behavioral change. Experts note its distinction from maintenance medications and potential wider applicability, including for depression and anxiety. The study’s inclusion of mostly Black participants is notable in a field often lacking diversity, and recruitment strategies avoided targeting psychedelic enthusiasts to reduce expectation bias. The promising results support moving to larger clinical trials.

A federal hemp ban scheduled to take effect in November threatens a new Medicare and Medicaid pilot program that reimburses patients for hemp-derived products. The ban would criminalize most CBD items by imposing strict THC limits, prompting industry advocates and lawmakers to push for delays or regulatory alternatives such as the Cannabinoid Safety and Regulation Act. Political gridlock has stalled legislative fixes, while lawsuits attempting to block the pilot program have failed. Advocates argue that regulators should focus on contamination rather than cannabinoid content, citing inconsistent safety standards across the hemp industry. Lawmakers remain uncertain whether Congress will act before the ban takes effect.

The administration announced overlapping drug policies that promote naloxone access while simultaneously cutting funding for fentanyl test strips, harm reduction messaging and broader overdose prevention efforts. Experts argue the cuts undermine an ambitious drug control strategy that depends on the very programs being defunded. Public health specialists note that test strips and drug-checking tools provide real-time information essential to preventing overdoses, while proposed Medicaid and budget reductions would further limit treatment capacity. Contradictions across agencies stem from poor coordination between budget and policy divisions, leading critics to warn the strategy is outdated and weakened by conflicting priorities.

A partial rescheduling order from the Trump administration moved state-licensed and prospective FDA‑approved medical cannabis products from schedule I to schedule III, prompting confusion among industry experts who say the change lacks clarity and leaves key implementation questions unresolved. Critics argue the decision is influenced by political timing, creates unequal treatment between medical and adult‑use cannabis, and may disproportionately disadvantage Black and Latino entrepreneurs. While the shift signals federal recognition of medical cannabis, it leaves broader legalization efforts uncertain as the DEA prepares for a new rescheduling hearing.

Analysts say the Trump administration’s executive order to expand access to psychedelic treatments carries more symbolic weight than legal impact, despite provisions for inter‑agency collaboration, research funding and accelerated rescheduling. Experts note growing Republican interest influenced by figures such as Joe Rogan and veteran advocates but warn that the administration’s veteran‑centered, medicalized framing may limit broader benefits. Comparisons to a prior cannabis rescheduling order highlight institutional resistance, particularly within the DEA. While several psychedelics are nearing FDA approval, concerns remain over accelerated review processes, potential reliance on AI and inadequate safeguards for adverse events. Specialists emphasize that expanded access must be paired with rigorous evidence, patient protections and broader public‑health investments.

Robert F Kennedy Jr’s new Secretary Kennedy Podcast largely echoes themes from his earlier show, promoting political talking points and past narratives about government dishonesty rather than substantive public health guidance. His previous podcast frequently aligned with anti-vaccine organization Children’s Health Defense and featured guests who challenged Covid-19 vaccines and government responses. As his political ambitions shifted, the show expanded into topics such as the economy and the war in Ukraine. The new podcast’s first episode, featuring Robert Irvine, focuses on general claims about diet-related chronic disease and argues food remains affordable, aligning with recent Trump administration messaging. Questions remain about whether the series will meaningfully address public health issues despite Kennedy’s promises to expose corruption and follow evidence.

Robert F Kennedy Jr and chef Robert Irvine used a government-produced podcast to argue that Americans could eat more affordably through smarter grocery choices, downplaying rising food costs. Their discussion omitted Trump administration policies, including tariffs and immigration crackdowns, that have contributed to those increases. An HHS spokesperson rejected claims of Trump-era responsibility for higher prices while overlooking reductions in Snap benefits. Kennedy repeated disputed assertions about diet-related causes of chronic disease and mental health conditions. The conversation emphasized messaging around healthier eating but offered little practical guidance for average families.

A CDC report shows a sharp rise in kratom-related poisonings in the US, which experts attribute to the spread of synthetic derivatives such as 7-OH rather than natural kratom. Researchers emphasize major differences between natural kratom and concentrated synthetic products, warning that blanket bans could harm people who rely on kratom for pain management or addiction recovery. Several users describe kratom as essential in managing withdrawal or chronic pain, while experts note it carries fewer risks than opioids but still presents concerns such as contamination, addiction potential and relapse-related overdose risk. Specialists argue natural kratom should remain available, with stricter regulation focused on synthetic derivatives.

A newly detected Omicron subvariant, BA.3.2, has appeared in 29 US states and Puerto Rico, but researchers report no evidence of increased severity or hospitalizations. Experts emphasize monitoring rather than alarm, noting that current vaccines continue to provide strong protection against severe disease. While the variant is overrepresented in pediatric sequencing data, scientists attribute this to testing patterns rather than increased risk to children. Public health guidance remains unchanged, though researchers will continue to track the strain for future vaccine updates.

Rising colon cancer rates among Americans under 40 coincide with widespread insurance denials for diagnostic colonoscopies, which are not fully covered for those under 45 under current Affordable Care Act rules. Experts warn that younger adults face dangerous delays due to coverage hurdles, misdiagnoses and referral loops. Personal accounts highlight high out‑of‑pocket costs that may deter timely testing. Researchers debate further lowering the recommended screening age but caution that limited specialist capacity and procedural risks require careful consideration. Alternatives such as stool tests may expedite approvals, while experts call for greater awareness of symptoms and intensified research into environmental and lifestyle exposures potentially driving the increase.

A scientific review in Lancet Psychiatry highlights concerns that AI chatbots may reinforce or amplify delusional thinking in individuals already vulnerable to psychosis. Psychiatric researchers describe how sycophantic or mystical chatbot responses, particularly from earlier models such as GPT‑4, can validate grandiose beliefs and accelerate the progression from attenuated delusions to fixed psychotic convictions. Experts stress that current evidence does not show AI inducing psychosis in people without prior vulnerability, preferring the term “AI‑associated delusions.” While AI companies such as OpenAI have implemented safety measures in newer models, problematic responses persist. Researchers warn that effective safeguards must avoid directly confronting delusional beliefs, a task that may exceed current chatbot capabilities.

Colorectal cancer has become the leading cause of cancer deaths among Americans under 50, with most younger patients diagnosed at advanced stages due to lack of screening and dismissal of early symptoms. Experts warn that rectal bleeding and bowel changes should prompt immediate medical evaluation, and note that stool-based screening tests can be an early alternative to colonoscopy. While rates continue to decline in older adults, younger generations face rising risks potentially linked to mid-20th‑century environmental or dietary changes. Alaska Natives experience the highest mortality rates worldwide, though limited population size hampers research funding. Survivors highlight the need for greater awareness, earlier detection, and discussions about fertility and sexual health before treatment begins.